ArticleJournal of molecular histology2026
Targeting ACTG1 alleviates isoproterenol-induced cardiac injury by regulating endothelial-to-mesenchymal transition.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathological mechanisms underlying cardiac fibrosis after isoproterenol (ISO)-induced cardiac injury remain poorly understood. Additionally, the biological function of ACTG1 in cardiovascular diseases has not been fully elucidated. This study aims to explore the role of ACTG1 and its regulatory mechanism in ISO-triggered cardiac injury and fibrosis. We established ISO-induced cardiomyocyte injury models and TGF-β1-stimulated vascular endothelial cell-endothelial-to-mesenchymal transition (EndoMT) models in vitro, and then evaluated the effects of ACTG1 silencing on cardiomyocyte functions and EndoMT progression in vascular endothelial cells. Conditioned medium (CM) and a TGF-β1 neutralizing antibody were applied to explore the paracrine crosstalk between cardiomyocytes and vascular endothelial cells. In vivo, an ISO-induced mouse model of cardiac injury was constructed to verify the regulatory effects of ACTG1 silencing on myocardial injury, fibrosis, inflammation, and EndoMT. The in vitro results demonstrated that ISO treatment upregulated ACTG1 expression at both the mRNA and protein levels in cardiomyocytes. Moreover, ACTG1 silencing attenuated ISO-induced cardiomyocyte injury and partially suppressed TGF-β1-mediated EndoMT in vascular endothelial cells. Further mechanistic experiments revealed that ACTG1 silencing in ISO-induced cardiomyocytes hindered EndoMT progression in vascular endothelial cells. TGF-β1 neutralization assays further confirmed that TGF-β1 acted as a key paracrine mediator linking cardiomyocyte activation to endothelial EndoMT. In addition, the silencing of ACTG1 in vivo attenuated myocardial injury, reduced collagen deposition, improved cardiac function, and downregulated the expression of EndoMT-related proteins in ISO-treated mice. ACTG1 exacerbated ISO-induced cardiomyocyte injury and facilitated EndoMT to promote cardiac injury and fibrosis, supporting ACTG1 as a promising therapeutic target for the treatment of cardiac injury.
Indexed as
Identifiers
42622896What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.